← Back to bk-2C-B

bk-2C-B Stats & Data

Psychedelic Research-chemical

bk-2cb bk-2-cb b-k-2cb b-k2cb b-k2-cb b-k2-c-b b-k-2-c-b bk2cb

PubChem CID 11288812

NPS DataHub

MW310.57

FormulaC10H13BrClNO3

CAS2303508-66-7

IUPACbeta-keto-2C-B

SMILES[Cl-].NCC(=O)c1cc(OC)c(Br)cc1OC.[H+]

InChIKeyQEGWLXAUBMCGTL-UHFFFAOYSA-N

Phenethylamines; Cathinones; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen

Chemical Class Phenethylamine

Psychoactive Class Psychedelic

Pharmacology

DrugBank

History & Culture

bk-2C-B was first characterized in the scientific literature in 2004 by pharmacologist Richard Glennon and his research team, who synthesized and studied the compound as part of investigations into phenethylamine structure-activity relationships. The substance remained largely obscure until 2013, when it emerged on European designer drug markets as a novel psychoactive substance. Following its market appearance, bk-2C-B maintained a consistent presence without generating significant enthusiasm or notoriety within the research chemical community. Despite this relatively muted reception, the compound was sampled by a substantial number of users over subsequent years. It was typically distributed in both pressed pill and powder forms. Its availability persisted in the gray market until regulatory measures were implemented across several countries beginning in 2016.

Toxicity

PsychonautWiki

The toxicity and long-term health effects of recreational βk-2C-B use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because Bk-2C-B is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried Bk-2C-B suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

Effect Profile

Curated + 31 Reports

Psychedelic 6.5

Strong visuals, auditory effects, and body load with mild headspace

Visual Intensity×3

1010

Headspace Depth×3

47.0

Auditory Effects×1

1010

Body Load / Somatic Effects×1

109.5

Catalog Erowid

Based on reports from:

Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki bk-2C-B The Drug Users Bible bk-2C-B

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Experience Report Analysis

Erowid

31 Reports

2012–2018 Date Range

30 With Age Data

26 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 31 experience reports (31 Erowid)

31 Reports

26 Effects Detected

10 Positive

8 Adverse

8 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 10

Euphoria 61.3% 70%

Music Enhancement 54.8% 70%

Color Enhancement 48.4% 70%

Empathy 48.4% 70%

Body High 48.4% 70%

Stimulation 48.4% 70%

Focus Enhancement 35.5% 70%

Introspection 19.4% 70%

Tactile Enhancement 19.4% 70%

Creativity Enhancement 9.7% 70%

Adverse Effects 8

Anxiety 51.6% 70%

Pupil Dilation 41.9% 70%

Confusion 38.7% 70%

Nausea 29.0% 70%

Sweating 19.4% 70%

Jaw Clenching 12.9% 70%

Headache 9.7% 70%

Increased Heart Rate 9.7% 70%

Dose-Response Correlation

How effect frequency changes across dose levels

View data table

Effect	Heavy (n=12)
Visual Distortions	100.0%
Color Enhancement	83.3%
Anxiety	66.7%
Euphoria	66.7%
Empathy	58.3%
Nausea	58.3%
Body High	58.3%
Confusion	50.0%
Music Enhancement	50.0%
Closed-Eye Visuals	41.7%
Open-Eye Visuals	41.7%
Stimulation	41.7%
Auditory Effects	41.7%
Pupil Dilation	41.7%
Focus Enhancement	33.3%

Dose–Effect Mapping

Experience Reports

How reported effects shift across dose tiers, based on 31 experience reports.

Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.

Oral dose range: 100.0–200.0 mg (median 150.0 mg)

Effect	Heavy (n=12)
visual distortions	100%
color enhancement	83%
anxiety	67%
euphoria	67%
empathy	58%
nausea	58%
body high	58%
confusion	50%
music enhancement	50%
closed-eye visuals	42%
open-eye visuals	42%
stimulation	42%
auditory effects	42%
pupil dilation	42%
focus enhancement	33%
hospital	33%
introspection	25%
tactile enhancement	25%
sedation	25%
sweating	25%

Showing top 20 of 28 effects

Dosage Distribution

Dose distribution from experience reports

Median: 150.0 mg IQR: 100.0–200.0 mg n=23

Real-World Dose Distribution

62K Doses

From 60 individual dose entries

Oral (n=51)

Median: 100.0mg 25th: 57.5mg 75th: 150.0mg 90th: 250.0mg

mg/kg median: 1.413 mg/kg 75th: 2.381

Form / Preparation

Most common forms and preparations reported

Body-Weight Dosing

Dose relative to body weight from reports with weight data

Median: 2.297 mg/kg IQR: 1.471–2.696 mg/kg n=22

Redose Patterns

Redosing behavior across 26 reports

38.5% Redosed

1.7 Avg Doses

120m Median Interval

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Canada	Controlled substance	Became a controlled substance in October 2016. Possession, production, and distribution are prohibited under Canadian drug scheduling.
Germany	Controlled substance	Classified as an illegal controlled substance. Manufacturing, possession, and distribution are prohibited without authorization.
Switzerland	Controlled substance	Listed as a controlled substance under Swiss narcotics legislation. Unauthorized possession and distribution are prohibited.
United Kingdom	Controlled (Psychoactive Substances Act 2016)	Prohibited under the Psychoactive Substances Act 2016, which broadly bans the production, supply, and importation of psychoactive substances intended for human consumption. Personal possession is not criminalized under this act, but supply-related offenses carry penalties of up to 7 years imprisonment.

← Back to bk-2C-B